Balance Sheet
Cash Flow Statement
AmortizationAmortizationAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Gains from Investment Securities (2020 - 2025)

Legend Biotech filings provide 6 years of Gains from Investment Securities readings, the most recent being -$877000.0 for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 101.42% to -$877000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $61.0 million, a 1.01% increase, with the full-year FY2023 number at -$663000.0, down 11.8% from a year prior.
  • Gains from Investment Securities hit -$877000.0 in Q3 2025 for Legend Biotech, down from $896000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $61.9 million in Q3 2024 to a low of -$918000.0 in Q2 2024.
  • Median Gains from Investment Securities over the past 5 years was -$39000.0 (2021), compared with a mean of $6.6 million.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 3800.0% in 2021 and later soared 235.14% in 2024.
  • Legend Biotech's Gains from Investment Securities stood at $40000.0 in 2021, then plummeted by 1582.5% to -$593000.0 in 2022, then fell by 11.8% to -$663000.0 in 2023, then soared by 235.14% to $896000.0 in 2024, then crashed by 197.88% to -$877000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were -$877000.0 (Q3 2025), $896000.0 (Q4 2024), and $61.9 million (Q3 2024) per Business Quant data.